TribLIVE

| Business


 
Larger text Larger text Smaller text Smaller text | Order Photo Reprints

Merck, Pfizer sue to block proposed version of AzaSite

Email Newsletters

Click here to sign up for one of our email newsletters.

On the Grid

From the shale fields to the cooling towers, Trib Total Media covers the energy industry in Western Pennsylvania and beyond. For the latest news and views on gas, coal, electricity and more, check out On the Grid today.

MRK $47.80 -$0.15

PFE $29.16 +$0.07

MYL $31.54 -$0.14

at close on MONDAY

By Bloomberg News
Tuesday, June 18, 2013, 12:01 a.m.
 

Merck & Co. and Pfizer Inc. sued generic drugmaker Mylan Pharmaceuticals Inc. to block it from selling a copy of AzaSite, an antibiotic eye solution for fighting bacterial conjunctivitis.

Mylan told Pfizer, Merck and InSite Vision Inc. on May 1 that it sought Food and Drug Administration approval to sell a generic version of AzaSite, according to a lawsuit filed on Friday in federal court in Trenton, N.J. The complaint asks a judge to prevent Mylan from entering the market before the patents expire. One ends in 2018, and the other three expire in 2019, according to the FDA website.

Subscribe today! Click here for our subscription offers.

 

 


Show commenting policy

Most-Read Business Headlines

  1. Pittsburgh’s tech startup activity rates last of 40 metro areas in report
  2. After years of downsizing, big houses make comeback
  3. New J.C. Penney CEO comes from middle-income America
  4. Floating homes offer ‘affordable’ option in San Francisco area
  5. Halliburton to close Indiana County office
  6. Corporate America speaking out on social issues, getting results
  7. Truffle dogs sniff out pungent fungus prized by foodies
  8. Aetna to buy rival Humana for $35B
  9. How to land that 1st job after college
  10. McDonald’s localizes menus to battle growing competition
  11. Airlines offer small conveniences to counter higher fees, less space